Therapeutic activities of PHA-L4, the mitogenic isolectin of phytohemagglutinin.
Evidence is presented that suggests that PHA-L4 may exert the therapeutic effects of a theoretical ideal biological response modifier through its ability to do the following: to assist remission induction in certain malignancies, to exhibit direct antitumor cytotoxic effects, to enhance antineoplastic effect of radiation and chemotherapy, to decrease the liability to malignant transformation, to promote differentiation and restore normal growth responses in neoplastic cells, to manifest minimal liability to suppressor activity that would inhibit tumor rejection or antitumor cytotoxicity, to repress graft rejection and graft-versus-host responses and amplify the immunosuppressive effects of other agents in allograft transplantations, to display a direct protective effect against damage from radiation and chemotherapy, to stimulate normal myelopoiesis, to reinforce responses against various infections, to amplify tumor immunogenicity, and to attract mononuclear cells to sites of injection or local application.
Wimer
B M
BM
Department of Medicine, Texas Tech University School of Medicine, Lubbock.
D000276:Adjuvants, Immunologic; D000741:Anemia, Aplastic / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D006801:Humans; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D007239:Infections / Q000188:drug therapy; D007694:Killer Cells, Natural / Q000187:drug effects; D008213:Lymphocyte Activation; D010835:Phytohemagglutinins / Q000494:pharmacology* / Q000627:therapeutic use; D011837:Radiation-Protective Agents
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D010835:Phytohemagglutinins; D011837:Radiation-Protective Agents; C064103:phytohemagglutinin L4